Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 1 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimus; tacrolimus monohydrate - hart forðahylki - 2 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 3 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s* - gabapentinum inn - hart hylki - 300 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - ciclosporinum inn - mjúkt hylki - 100 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - ciclosporinum inn - mjúkt hylki - 25 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - ciclosporinum inn - mjúkt hylki - 50 mg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s* - sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50 mg

Euroopan unioni - islanti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - sveppalyf fyrir almenn nota - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Euroopan unioni - islanti - EMA (European Medicines Agency)

pfizer europe ma eeig - anidulafungin - candidiasis - sveppalyf fyrir almenn nota - meðferð innrásar sveppasýkingu í fullorðna og börn sjúklinga á aldrinum 1 mánuð til að < 18 ára.